Peptide Order Rau Cov Neeg Siv Khoom Tshiab

Lub nra hnyav thoob ntiaj teb ntawm ntshav qab zib thiab rog rog tau mus txog qhov sib kis sib kis, nrog rau Lub Koom Haum Saib Xyuas Kev Noj Qab Haus Huv Ntiaj Teb (WHO) tau tshaj tawm ntau dua 537 lab tus neeg laus nyob nrog ntshav qab zib thoob ntiaj teb thiab ze li 2 billion suav tias rog dhau lossis rog. Cov txheej txheem kev kho mob feem ntau poob qis hauv kev hais txog kev sib cuam tshuam ntawm kev tswj glycemic, tswj qhov hnyav, thiab txo qis kev pheej hmoo ntawm lub plawv.Tirzepatide, thawj-hauv-chav kawm dual qabzib-nyob ntawm insulinotropic polypeptide (GIP) thiab glucagon-zoo li peptide-1 (GLP-1) receptor agonist, tau tshwm sim los ua kev kho mob hloov pauv los ntawm ib txhij tsom mus rau ntau txoj hauv kev metabolic. Kab lus no tshawb txog nws cov txheej txheem ntawm kev nqis tes ua, kev kho mob ua tau zoo, kev ruaj ntseg profile, thiab kev hloov kho cov ntawv thov.

Tirzepatide yog 39-amino acid synthetic peptide engineered nrog C20 fatty diacid moiety, ua rau albumin khi thiab txuas nws ib nrab-lub neej mus txog li 5 hnub-ib qho kev txhawb nqa nws ib zaug - noj txhua lub lim tiam. Nws ob lub receptor agonism sib txuas cov txiaj ntsig tsim los ntawm GLP-1 receptor activation nrog cov teebmeem tshiab GIP-mediated, tsim kom muaj kev cuam tshuam metabolic.

● GLP-1 Receptor Pathway

GLP-1 receptor activation txhim kho cov piam thaj- nyob ntawm cov tshuaj insulin tso tawm los ntawm pancreatic -cells, inhibits glucagon tso tawm ntawm -cells, qeeb plab hnyuv plab, thiab txo qis qab los ntawm lub hauv nruab nrab paj hlwb (CNS) signaling. Cov teebmeem no ua ke txo qis kev mus ncig ua si tom qab noj mov thiab txhawb kev poob phaus los ntawm kev txo cov calories kom tsawg.

● GIP Receptor Pathway

GIP, ib txwm hu ua "incretin hormone," nthuav tawm cov ntsiab lus - nyob ntawm kev ua:

Hyperglycemic States: inhibits glucagon secretion thiab nkoos insulin tso tawm, augmenting GLP-1 cov teebmeem hypoglycemic.

Euglycemia/Hypoglycemia: Txhawb nqa glucagon secretion, tiv thaiv kev tawm dag zog- lossis yoo mov-induced hypoglycemia-ib qho zoo dua li GLP-1 monotherapy.

Adipose ntaub so ntswg: Txhim kho lipolysis thiab fatty acid oxidation, txo ectopic fat deposition.

CNS Cov teebmeem: Hloov kho kev noj qab haus huv thiab kev siv hluav taws xob, ntxiv rau GLP-1's anorexigenic ua.

Qhov kev siv ob npaug no tso cai rau tirzepatide los daws ntau yam kev ua haujlwm ntawm metabolic, suav nrog hyperglycemia, insulin tsis kam, thiab adiposity, nrog kev ua tau zoo dua li ib leeg -receptor agonists.

Hom 2 Diabetes Management

Tirzepatide qhov kev pom zoo rau hom 2 mob ntshav qab zib mellitus (T2D) hauv xyoo 2022 yog ua raws li SURPASS qhov kev pab cuam, kev sim ntawm theem 3 piv rau cov placebo, insulin glargine, thiab semaglutide (GLP-1 receptor agonist). Cov txiaj ntsig tseem ceeb suav nrog:

Glycemic Control: Hauv SURPASS-1, cov neeg mob tau txais 15 mg tirzepatide tau ua tiav qhov kev txo qis HbA1c ntawm 2.58% los ntawm lub hauv paus (vs . 1.44% nrog semaglutide 1 mg). Hauv kev sim, 52-66% ntawm cov neeg mob tau mus txog HbA1c<7% without severe hypoglycemia.

Poob qhov hnyav: Tirzepatide induced koob- nyob ntawm qhov hnyav ntawm 7.5-12.9 kg (15-22 lb) tshaj 40-52 lub lis piam, tshaj semaglutide's 6.2 kg (13.7 lb) poob hauv taub hau- rau- taub hau

Cov txiaj ntsig plawv: Cov ntaub ntawv ua ntej qhia txog kev txo cov ntshav siab thiab triglycerides, nrog rau kev sim tsis tu ncua ntsuas qhov tshwm sim tsis zoo ntawm cov hlab plawv (MACE).

Kev kho mob rog

Tirzepatide's 2023 kev pom zoo rau kev tswj qhov hnyav hauv cov neeg laus uas muaj rog rog (BMI Ntau dua lossis sib npaug li 30 kg / m²) lossis rog dhau (BMI Ntau dua lossis sib npaug li 27 kg / m²) nrog kev sib xyaw ua ke tau tsav los ntawm SURMOUNT program:

SURMOUNT-1: Cov neeg mob ntawm 15 mg tirzepatide poob 22.5 kg (49.9 lb) dhau 72 lub lis piam, sawv cev 20.9% ntawm qhov hnyav hauv qab. Ze li ntawm ib feem peb tau ua tiav Ntau dua lossis sib npaug li 25% poob phaus, qhov tseem ceeb tsis sib xws los ntawm cov kws kho mob uas twb muaj lawm.

SURMOUNT-2: Hauv cov neeg mob uas muaj T2D, tirzepatide txo qhov hnyav los ntawm 15.7% (vs . 3.6% nrog cov placebo), ua kom pom kev ua tau zoo hauv pawg no muaj kev pheej hmoo siab.

SURMOUNT-OSA: Hauv obstructive pw tsaug zog apnea (OSA) cov neeg mob, tirzepatide txo qhov apnea -hypopnea index (AHI) los ntawm 27–30 txheej xwm / teev thiab txo lub cev hnyav los ntawm 18–20%, muab ib qho tshiab uas tsis yog -invasive kho rau tus mob no.

Cov txiaj ntsig no tso cai rau tirzepatide ua cov tshuaj tiv thaiv kev rog zoo tshaj plaws rau hnub tim, nrog kev ua tau zoo piv rau kev phais bariatric hauv cov neeg xaiv.

Tirzepatide's kev nyab xeeb profile feem ntau yog ua raws li GLP-1 receptor agonists, nrog rau cov tsos mob ntawm plab hnyuv (GI) yog cov xwm txheej tsis zoo (AEs):

GI kam rau ua: xeev siab (31–39%), raws plab (19–23%), thiab ntuav (15–18%) tshwm sim feem ntau thaum noj tshuaj (2.5 mg increments txhua 4 lub lis piam). Cov tsos mob no yog mob me -rau- nruab nrab thiab ib ntus, feem ntau daws tau hauv 4-8 lub lis piam.

Hypoglycemia: Tus nqi qis (<5%) due to glucose-dependent receptor activation, though caution is advised when co-prescribed with sulfonylureas or insulin.

Txhaj tshuaj -Qhov Kev Ua Phem: Tsis tshua muaj (<5%) and mild, managed with proper injection technique.

Ntev-Lub Sij Hawm Kev Nyab Xeeb: Cov ntaub ntawv los ntawm Ntau dua lossis sib npaug rau 2- xyoo txuas ntxiv ntawm SURPASS thiab SURMOUNT kev sim qhia tsis muaj cov cim kev nyab xeeb tshiab, nrog rau lub raum ruaj khov thiab ua haujlwm siab. Kev soj ntsuam tom qab kev lag luam txuas ntxiv soj ntsuam cov xwm txheej tsis tshua muaj xws li mob pancreatitis thiab medullary thyroid carcinoma (kev pheej hmoo ntawm kev xav, zoo li txhua tus neeg ua haujlwm GLP-1).

Cov tswv yim los txo cov AEs suav nrog kev siv tshuaj qeeb qeeb, kev kawm ntawm tus neeg mob txog dej / khoom noj khoom haus, thiab kev kho mob (xws li, tshuaj tiv thaiv rau xeev siab). Cov tshuaj tau txais txiaj ntsig hauv kev txo cov ntshav qab zib mellitus- cuam tshuam txog cov teeb meem thiab kev txhim kho lub neej zoo feem ntau ntau dua qhov tsis xis nyob.

Tirzepatide's dual mechanism thiab kev ua tau zoo muaj zog tau txhawb kev tshawb nrhiav rau nws lub luag haujlwm hauv lwm yam kev mob metabolic thiab mob plawv:

Tsis yog-Alcoholic Steatohepatitis (NASH): Thaum ntxov- kev sim theem qhia txog kev txo qis hauv daim siab rog thiab fibrosis cov cim, nrog rau theem 3 kev tshawb fawb tab tom pib.

Heart Failure with Preserved Ejection Fraction (HFpEF): Tsiaj cov qauv qhia kev txhim kho diastolic muaj nuj nqi thiab kev ua siab ntev, ua rau muaj kev sim tshuaj nyob rau hauv cov neeg tsis tau txais kev pab.

Polycystic Ovary Syndrome (PCOS): Cov kev tshawb fawb me me qhia txog kev txhim kho kev coj khaub ncaws tsis tu ncua thiab cov metabolism hauv cov poj niam uas muaj PCOS thiab rog.

Kev paub tsis meej: Cov ntaub ntawv qhia ua ntej qhia txog cov teebmeem neuroprotective los ntawm kev txo qhov mob thiab amyloid-beta tsub zuj zuj, ua rau muaj kev txaus siab rau kev tiv thaiv kab mob Alzheimer.

Cov ntawv thov tshawb fawb no qhia txog tirzepatide lub peev xwm los kho cov tshuaj metabolic dua li nws cov lus qhia tam sim no.

Tirzepatide txoj kev lag luam ua tiav tsis tau muaj dhau los, nrog kev muag khoom thoob ntiaj teb ntau dua $ 11 nphom hauv 2024, tau tsav los ntawm kev xav tau muaj zog hauv kev lag luam ntshav qab zib thiab rog rog. Nws dominance yog los ntawm:

Kev ua tau zoo tshaj plaws: Ua tau zoo tshaj GLP-1 agonists uas twb muaj lawm hauv kev poob phaus thiab tswj glycemic.

Kev Siv Yooj Yim: Ib zaug- kev tswj hwm txhua lub limtiam txhim kho kev ua raws li cov kev xaiv niaj hnub.

Kev nthuav qhia nthuav dav: Kev pom zoo hauv OSA thiab cov ntaub ntawv tseem ceeb rau HFpEF thiab NASH tuaj yeem nthuav dav nws txoj kev lag luam mus txog.

Kev txhim kho yav tom ntej muaj xws li:

Oral Formulations: Kev siv zog xa tirzepatide ntawm cov ntsiav tshuaj ntawm qhov ncauj tuaj yeem txhim kho kev nkag mus tau ntxiv.

Kev sib xyaw ua ke: Kev sib koom ua ke nrog SGLT2 inhibitors lossis cov neeg ua haujlwm tshiab xws li qabzib -nyob ntawm insulinotropic polypeptide receptor antagonists (GIPRAs) tuaj yeem ua rau muaj txiaj ntsig ntxiv.

Cov Tshuaj Kho Mob Tus Kheej: Biomarker- tau tsav txoj hauv kev los txheeb xyuas cov neeg teb thiab ua kom zoo dua

Tirzepatide sawv cev rau kev hloov pauv hauv kev tswj cov kab mob metabolic, siv dual GIP / GLP-1 receptor agonism kom ua tiav qhov tsis tau pom dua glycemic tswj, poob phaus, thiab txo qis kev pheej hmoo ntawm cov hlab plawv. Nws qhov kev nyab xeeb muaj txiaj ntsig zoo thiab nthuav dav cov kev qhia kho mob tso nws ua lub hauv paus ntawm kev kho mob ntshav qab zib niaj hnub thiab kev rog rog. Raws li kev tshawb fawb txuas ntxiv mus nthuav tawm nws lub peev xwm tag nrho, tirzepatide tuaj yeem ua txoj hauv kev rau lub sijhawm tshiab ntawm cov tshuaj precision, qhov twg cov kev kho mob ntau lub hom phiaj hais txog lub hauv paus ua rau metabolic tsis ua haujlwm ntau dua li tsuas yog tswj cov tsos mob. Rau cov neeg mob thiab cov kws kho mob ib yam nkaus, tirzepatide tsis yog tsuas yog kev kho mob xwb, tab sis kuj yog lub cuab yeej hloov pauv hauv ntiaj teb kev sib ntaus sib tua tiv thaiv kab mob metabolic.